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SHOULD LIVER TRANSPLANTS BE PERFORMED FOR
MALIGNANT DISEASE?
ABSTRACT
O’Grady, J.G., Poison, R.J., Rolles, K., Calne, R.Y., Williams, R. (1988)
Liver Transplantation for Malignant Disease" Results in 93 consecutive patients.
Annals of Surgery, 207,373-9.
Ninety-three patients with malignant disease underwent orthotopic liver transplantation
between May 1968 and April 1987 in the Cambridge/King’s Hospital program. Of 50
patients with primary hepatocellular carcinoma (HCC) (19 with cirrhosis, 31 without
cirrhosis, including 7 with fibrolamellar variant), 37 (74%) survived for more than 3
months, and in this group evidence of tumor recurrence was obtained in 24 (64.9%), the
longest survivor being 11.8 years post-transplant, and three survived for more than 5
years. Although there is no correlation between the frequency of tumor recurrence and
underlying cirrhosis, or histologic type (except fibrolamellar variant), it was observed
earlier in those with moderate/poorly differentiated tumors and also when prednisolone
and azathioprine was used for immunosuppression. Tumor recurred in all but two ofthose
with peripheral or central cholangiocarcinoma (one alive at 6.1 years) with median
survival times of34 weeks and 56 weeks for the central and peripheral types, respectively.
Among the unusual primary tumors, one with epithelioid haemangioendothelioma
developed tumor recurrence at 2 years, one oftwo patients with apudoma is tumor-free at
2.2 years, and the one patient with bile-duct papillary cystadenocarcinoma is alive at 1.7
years. For the secondary hepatic malignancy group, survival times were shorter with little
palliation except for two patients with carcinoid syndrome who were free.
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DISCUSSION
The traditional surgical ethos of cancer treatment is to obtain a cure by removing all
malignant tissue. Primary liver cell cancer, often associated with cirrhois, is probably
the world’s commonest primary malignancy and secondary tumour deposits in the
liver are frequently seen by all surgeons. In both cases surgeons argue that resection
will lead to an improved prognosis. However hard data to prove this is difficult to find
and some caution is needed before reaching this conclusion1. When tumour
replacement of the liver parenchyma is so great that resection of all of it is impossible
without removing the whole organ, transplantation should be the ideal approach. Is
it?
Starzl’s team has grave doubts arguing that the vast majority of such patients have
recurrence of malignancy within one to four years of successful transplantation2. The
longest survivors in their series are patients with the fibrolamellar varient of primary
liver cell cancer and those in whom a cancer was found in the recipient’s liver
incidentally after transplantation had been carried out for some other reason3.
Conversely Pichlmayr argues, ’But all these arguments (on value and justification)
are somewhat problematic and should be negated if life saving prolongation in a good
state of health could possibly by achieved’4.
The team headed by Professor Roy Calne and Dr Roger Williams at King’s
College Hospital, London and Addenbrooke’s Hospital, Cambridge, England now
reports its results of 93 liver graft operations carried out for malignant disease of the
liver. Twelve of 50 patientswho had primary hepatocellular cancer survived formore
than one year including two who were tumour free at death over five years after
transplantation. Of the ten still alive, six are tumour free, one at 4.8 and one at 11.8
years. The presence of cirrhosis did not significantly affect the outcome. Of the seven
patients with the fibrolamellar varient, three died with recurrence, one died at 5.8
years from transplant related problems but was tumour free and three are alive and
tumour free at three months, 1.8 and 4.5 years.
Of 26 patients with cholangiocarcinoma, only one is alive and tumour free at 6.5
years. The median survival for patients with central cholangiocarcinoma was 34
weeks and with peripheral tumour 56 weeks. In a recent review Starzl’s group lists
this type of tumour as a ’relative contraindication’ to transplantation2. However
Pichlmayr claims a hundred per cent one year survival for ’proximal bile duct
tumours in lymphnode negative stages’ but only 13% one year survival if
lymphnodes were involved4 and he argues that making the presence of bile duct
tumours a contraindication to transplantation may be ’premature at the present.’
Two out of nine of the transplants for ’rare malignancies’ are tumour free and well
at 20 months and 2.2 years. The rest have succumbed.
Of the six patients who were transplanted for metastatic disease none survived
more than 41 weeks. One of two patients transplanted for carcinoid syndrome
remains symptom free at 12 months despite rising levels of 5 HIAA.
This well documented paper constitutes a major contribution to the debate but
firm conclusions are still difficult to reach. At a simplistic level it would appear that
if the malignant process is totally confined to the liver and it can be removed and
replaced with a good new organ then cure is effected. However this is onlyHPB INTERNATIONAL 241
occasionally possible. In most cases at the time of transplantation the tumour has
already seeded outside the liver and it is these metastases which ultimately contribute
to the patient’s death. Certainly the morbidity and mortality of the surgical
procedure is now improving.
Liver transplantation for malignant disease is an attractive surgical procedure
since many patients (in the West) do not suffer concomitant cirrhosis (19 out of 50 in
this study) and thus the operation is usally technically straightforward without the
excessive haemorrhage associated with portal hypertension.
Can we identify the suitable candidates for this procedure? It would appear that
patients with fibro lamellar varient of primary liver cell cancer and those with a
proximal cholangiocarcinoma and no involved nodes fare best. It is difficult to advise
transplantation for secondary tumours despite occasional reports of successful
operations. The ideal patient will be one in whom resection of the tumour is
impossible because of its extent but in whom there is no seeding outside the liver.
Identification of these patients is difficult. Macroscopic tumours can be readily
identified by conventional imaging such as ultrasound, CT or at laparotomy.
However micrometastases cannot be found. We have to await further developments
of targeted markers in the molecular biology laboratories before they can.
What should be done in the meantime? Liver transplantation is now an acceptable
surgical operation and major centres will continue to practise it in an attempt to treat
malignant disease affecting the liver. They should continue to do so but healthy,
critical caution must be exercised when advising this treatment which is expensive in
terms of money and patient discomfort and still does not carry any guarantee of
success. Some patients with confined tumours will benefit and gain a few extra
months or even years of life. The results of prospective controlled trials would be
interesting but they are probably impossible to mount and anyway will probably fail
to give any help in decision making for an individual patient. Hopefully further work
in the basic science laboratories will bear fruit and allow us to select (the few) ideal
candidates in the future.
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Over 40 years ago, Mixter and his associates demonstrated that cholangiovenous
reflux occurs when contrast media is injected into the bile duct. Twenty years ago
Huang et al2 demonstrated in dogs that cholangiovenous reflux of Escherichia coli is
directly related to biliary pressure. These investigators also showed that
cholangiolymphatic reflux of bacteria occurs at the same levels of intrabiliary_
pressure which cause cholangiovenous reflux. In 1984 Yamamoto and Phillips
3
performed corrosion-cast experiments in rats and noted filling of periportal
lymphatic spaces after biliary injection. One theoretical problem with this study,
however, was the relatively high viscosity of the casting compound. Therefore,
Stewart et al4 have recently repeated these studies with a lower viscosity mixture
which approximates the viscosity of bile.
The findings of Stewart et al4 confirm the earlier observations of Yamamoto and
Phillips3. These studies have demonstrated that cholangiovenous reflux in the rat
progresses from the proximal bile ductules into 1) the spaces ofMall and Disse, 2) the
hepatic sinusoids, and 3) the collecting veins. This process occurs without filling of
bile canaliculi and without disruption of hepatocytes. Moreover, particles of 1.7 Ix or
smaller were able to reflux in this manner whereas particles of 10Ix size did not reflux.
This observation is consistent with previous studies which have demonstrated that
bacteria can reflux into both the hepatic veins and lymphatics while erythrocytes,
which are 6 or 7p. in diameter, are too large to reflux even at high pressures.
An interesting additional observation made by Stewart et al4 was that the
"resistance" to reflux varied as this process occurred progressively into 1) the spaces
of Mall and Disse, 2) the hepatic sinusoids, and 3) the collecting veins. Resistance,
as measured from pressure/volume relationships, increased as reflux progressed
from the bile ductules into the spaces of Mall and Disse at pressures from 20 to 50 cm
of water. Resistance then decreased to values observed during biliary ductal filling as
reflux continued into the hepatic sinusoids at pressures from 50 to 80 cm of water.
Resistance then fell to practically zero as reflux progressed into the hepatic collecting
veins at pressures of approximately 80 cm of water.
These "resistance" data were obtained by retrograde injection into the common
bile duct at a constant rate of 0.04 ml/min and correlated with electron microscopy.
An interesting extension of these studies would be to measure resistance and observe
reflux pathways at different flow rates. Clinically, cholangitis, and therefore reflux,
is most likely to occur with rapid increases in intrabiliary pressure. The question
remains, therefore, whether the reflex pathways observed by Stewart et al4 would be
altered by different flow rates. If the infusions had been more rapid, would the
pathways have differed and would "high-resistance pathways" such as biliary
canaliculi or hepatocytes have been involved?
Another interesting question is the relative contribution of cholangiovenous and
cholangiolymphatic reflux to clinical eholangitis. The studies by Yamamoto and
Phillips
3 and by Steward et al4 both suggest that cholangiolymphatic reflux occurs
before and at lower pressures than cholangiovenous reflux. This observation
suggests that if intrabiliary pressures are raised to only moderate levels (20 to 50 cm
ofwater) cholangiolymphatic reflux may be the only route for bacteria to gain access,
via the thoracic duct, to the venous system. This scenario would be possible because
at pressures below 50 cm ofwater Stewart et al4 did not observe reflux into the hepatic
sinusoids or collecting veins.HPB INTERNATIONAL 243
Another issue that must be considered is the relevance of these rat studies to man.
Humans and many other species have a gallbladder, but the rat does not. One of the
important functions of the gallbladder is to absorb water and, thereby, concentrate
bile. In the face of distal biliary obstruction, the absorptive function of the
gallbladder may actually moderate intrabiliary pressures and keep them below the
hepatic secretary pressure. Thus, a species such as the rat, which does not have a
gallbladder, may have reflux pathways that are different from those present in man.
Conformation of the studies by Stewart et al4 in a species with a gallbladder would
add credence to their observations.
A third point that must be considered when interpreting these corrosion casting
studies is the similarity of the casting compound to bile. Stewart et al4 have attempted
to improve upon the study by Yamamoto and Phillips by lowering the viscosity of
the casting compound. Stewart and her colleagues demonstrated quite nicely that the
addition of inert ceramic particles of different sizes dramatically affected "reflux
pathways." What would they have observed, however, had they also studied the
effect of varying the osmolality or pH of the casting compound?
For clinical cholangitis to occur two factors must be present" 1) increased
intrabiliary pressure and 2) bacteria. The presence of bacteria in bile, however, may
actually change its chemical character. Bacteria may secrete glycoproteins and
enzymes. Bacterial enzymes may deconjugate both bilirubin and bile salts.
Deconjugated bile salts are more likely to diffuse into and damage cells and, thereby,
increase their permeability. Another interesting study, therefore, would be to add
deconjugated bite-salts to the casting compound.
Finally, various bacteria may either enhance or impede cholangiovenous or
cholangiolymphatic reflux. Possible enhancing mechanisms have been mentioned
above. Could the bacterial production of mucus glycoproteins actually block reflux
pathways? Alternatively, could the presence ofpili on certain bacteria promote their
attachment to ductal epithelial cells and, thereby, inhibit reflux? Thus, as with many
good studies, the work of Stewart et al4 may have raised more questions than were
answered. Hopefully, future studies on the pathogenesis of cholangitis will address
1) the rate of pressure rise, 2) the influence of species difference, 3) the impact of bile
composition, and 4) variable effects of different bacteria.
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